Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data

作者全名："Feng, Guowen; Zhou, Xiaodan; Chen, Jia; Li, Dan; Chen, Li"

作者地址："[Feng, Guowen; Zhou, Xiaodan; Chen, Jia; Li, Dan; Chen, Li] Sichuan Univ, West China Second Univ Hosp, Dept Pharm, Chengdu, Sichuan, Peoples R China; [Feng, Guowen; Zhou, Xiaodan; Chen, Jia; Li, Dan; Chen, Li] Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Childr, Minist Educ, Chengdu, Sichuan, Peoples R China; [Feng, Guowen] Peoples Hosp Langzhong, Dept Pharm, Langzhong, Sichuan, Peoples R China; [Zhou, Xiaodan] Chongqing Med Univ, Univ Town Hosp, Chongqing, Peoples R China; [Chen, Jia] Sichuan Prov Peoples Hosp, Jinniu Hosp, Dept Pharm, Chengdu, Sichuan, Peoples R China; [Li, Dan] First Peoples Hosp Bijie City, Bijie, Guizhou, Peoples R China"

通信作者："Chen, L (通讯作者)，Sichuan Univ, West China Second Univ Hosp, Dept Pharm, Chengdu, Sichuan, Peoples R China.; Chen, L (通讯作者)，Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Childr, Minist Educ, Chengdu, Sichuan, Peoples R China."

来源：FRONTIERS IN ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000917833000001

JCR分区：Q2

影响因子：3.5

年份：2023

卷号：12

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：platinum drugs; FAERS; adverse event; date mining; ADE signals

摘要："BackgroundWith the widespread application of platinum drugs in antitumor therapy, the incidence of platinum drug adverse events (ADEs) is always severe. This study aimed to explore the adverse event signals of Cisplatin, Carboplatin and Oxaliplatin, three widely used platinum-containing drugs, and to provide a reference for rational individualized clinical drug use. MethodsThe adverse event report data of the three platinum drugs from the first quarter of 2017 to the fourth quarter of 2021 were extracted from the FAERS database, and the data mining and risk factors for the relevant reports were carried out using the reporting odds ratio (ROR) method the proportional reporting ratio (PRR)and the comprehensive criteria (MHRA) method. ResultsA total of 1853 effective adverse event signals were obtained for the three platinum agents, including 558 effective signals for Cisplatin, 896 effective signals for Carboplatin, and 399 effective signals for Oxaliplatin. The signals involve 23 effective different system organs (SOCs). The adverse events of Cisplatin are mainly fixed on blood and lymphatic system diseases, gastrointestinal diseases, systemic diseases and various reactions at the administration site. The adverse events of Carboplatin are mainly focused on blood and lymphatic system diseases, respiratory system, thoracic and mediastinal diseases, while the adverse events of Oxaliplatin are mainly concentrated in respiratory system, thoracic and mediastinal diseases, various nervous system diseases, and gastrointestinal system diseases. ConclusionIt was found that the main systems involved in common adverse events of platinum drugs are different, and the correlation strength of platinum drugs with the certain adverse events of each system is different."

基金机构：National Natural Science Foundation of China [82073921]

基金资助正文：Funding This work was supported by grants from the National Natural Science Foundation of China (82073921).